Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment

Environmental Toxicology

Volumn 28, Issue 5, 2013, Pages 267-275

  Wang, Huihui ^a   Xi, Shuhua ^a   Liu, Zhuogang ^a   Yang, Ying ^a   Zheng, Quanmei ^a   Wang, Fei ^a   Xu, Yuanyuan ^b   Wang, Yi ^a   Zheng, Yi ^a   Sun, Guifan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Acute promyelocytic leukemia; Arsenic methylation; Arsenic trioxide; Liver injury; Urinary arsenic species

Indexed keywords

ARSENIC TRIOXIDE; ENVIRONMENTAL TOXICANTS; LIVER FUNCTIONS; LIVER INJURIES; METHYLATION CAPACITY; PROMYELOCYTIC LEUKEMIA; STATISTICAL DIFFERENCES; URINARY ARSENIC;

ALKYLATION; BLOOD; DISEASES; METABOLISM; METHYLATION; PATIENT MONITORING; PATIENT TREATMENT; PHYSIOLOGY;

ARSENIC;

AMINOTRANSFERASE; ARSENIC TRIOXIDE;

ARSENIC; BLOOD; CANCER; INJURY; METABOLISM; METABOLITE; METHYLATION; URINE;

ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD EXAMINATION; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; HUMAN; LEUKOCYTOSIS; LIVER FUNCTION; LIVER INJURY; MALE; METHYLATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SEX DIFFERENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ARSENICALS; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTOSIS; LIVER; LIVER FUNCTION TESTS; MALE; METHYLATION; MIDDLE AGED; OXIDES; SEX FACTORS; YOUNG ADULT;

EID: 84876433093     PISSN: 15204081     EISSN: 15227278     Source Type: Journal    
DOI: 10.1002/tox.20717     Document Type: Article

References (62)

1. Aposhian HV. 1997. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu Rev Pharmacol Toxicol 37: 397-419.
2. Aposhian HV, Zakharyan RA, Avram MD, Sampayo-Reyes A, Wollenberg ML. 2004. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol Appl Pharmacol 198: 327-335.
3. Bates MN, Smith AH, Hopenhayn-Rich C. 1992. Arsenic ingestion and internal cancers: A review. Am J Epidemiol 135: 462-476.
4. Berenson JR, Yeh HS. 2006. Arsenic compounds in the treatment of multiple myeloma: A new role for a historical remedy. Clin Lymphoma Myeloma 7: 192-198.
5. Chen CJ, Chen CW, Wu MM, Kuo TL. 1992. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66: 888-892.
6. Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Chao SC, Lee JY, Christiani DC. 2003a. Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45: 241-248.
7. Chen YC, Su HJ, Guo YL, Houseman EA, Christiani DC. 2005. Interaction between environmental tobacco smoke and arsenic methylation ability on the risk of bladder cancer. Cancer Causes Control 16: 75-81.
8. Chen YC, Su HJ, Guo YL, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Christiani DC. 2003b. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 14: 303-310.
9. Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. 2001. Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies. Semin Hematol 38: 26-36.
10. Chowdhury UK, Rahman MM, Sengupta MK, Lodh D, Chanda CR, Roy S, Quamruzzaman Q, Tokunaga H, Ando M, Chakraborti D. 2003. Pattern of excretion of arsenic compounds [arsenite, arsenate. MMA(V), DMA(V)] in urine of children compared to adults from an arsenic exposed area in Bangladesh. J Environ Sci Health A Tox Hazard Subst Environ Eng 38: 87-113.
11. Chung JS, Kalman DA, Moore LE, Kosnett MJ, Arroyo AP, Beeris M, Mazumder DN, Hernandez AL, Smith AH. 2002. Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. Environ Health Perspect 110: 729-733.
12. Cohen SM, Arnold LL, Eldan M, Lewis AS, Beck BD. 2006. Methylated arsenicals: The implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit Rev Toxicol 36: 99-133.
13. Concha G, Vogler G, Nermell B, Vahter M. 2002. Intra-individual variation in the metabolism of inorganic arsenic. Int Arch Occup Environ Health 75: 576-580.
14. Del Razo LM, Garcia-Vargas GG, Vargas H, Albores A, Gonsebatt ME, Montero R, Ostrosky-Wegman P, Kelsh M, Cebrian ME. 1997. Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. A pilot study. Arch Toxicol 71: 211-217.
15. Engel RR, Hopenhayn-Rich C, Receveur O, Smith AH. 1994. Vascular effects of chronic arsenic exposure: A review. Epidemiol Rev 16: 184-209.
16. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D, Huebner G, Bauters F, Fegueux N, Fey M, Sanz M, Lowenberg B, Maloisel F, Auzanneau G, Sadoun A, Gardin C, Bastion Y, Ganser A, Jacky E, Dombret H, Chastang C, Degos L, the European APL 91 Group. 1993. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 82: 3241-3249.
17. Gamble MV, Liu X, Ahsan H, Pilsner R, Ilievski V, Slavkovich V, Parvez F, Levy D, Factor-Litvak P, Graziano JH. 2005. Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh. Environ Health Perspect 113: 1683-1688.
18. Gebel TW. 1999. Arsenic and drinking water contamination. Science 283: 1458-1459.
19. Gebel TW. 2002. Arsenic methylation is a process of detoxification through accelerated excretion. Int J Hyg Environ Health 205: 505-508.
20. Georis B, Cardenas A, Buchet JP, Lauwerys R. 1990. Inorganic arsenic methylation by rat tissue slices. Toxicology 63: 73-84.
21. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, et al. 2006. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 17: 131-134.
22. Graeme KA, Pollack CVJr. 1998. Heavy metal toxicity. Part I: Arsenic and mercury. J Emerg Med 16: 45-56.
23. Hayakawa T, Kobayashi Y, Cui X, Hirano S. 2005. A new metabolic pathway of arsenite: Arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch Toxicol 79: 183-191.
24. Healy SM, Casarez EA, Ayala-Fierro F, Aposhian H. 1998. Enzymatic methylation of arsenic compounds. V. Arsenite methyltransferase activity in tissues of mice. Toxicol Appl Pharmacol 148: 65-70.
25. Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE. 1996. Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect 104: 620-628.
26. Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH, Lue LC, Chen GS, Chen CJ. 1997. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 6: 589-596.
27. IARC. 2004. Some drinking-water disinfectants and contaminants, including arsenic. IARC Monogr Eval Carcinog Risks Hum 84: 1-477.
28. Kitchin KT. 2001. Recent advances in arsenic carcinogenesis: Modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 172: 249-261.
29. Li X, Li B, Xu Y, Wang Y, Jin Y, Itoh T, Yoshida T, Sun G. 2011. Arsenic methylation capacity and its correlation with skin lesions induced by contaminated drinking water consumption in residents of chronic arsenicosis area. Environ Toxicol 26: 118-123.
30. Liu J, Waalkes MP. 2008. Liver is a target of arsenic carcinogenesis. Toxicol Sci 105: 24-32.
31. Loffredo CA, Aposhian HV, Cebrian ME, Yamauchi H, Silbergeld EK. 2003. Variability in human metabolism of arsenic. Environ Res 92: 85-91.
32. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M. 2006. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 107: 2627-2632.
33. Mazumder DN. 2005. Effect of chronic intake of arsenic-contaminated water on liver. Toxicol Appl Pharmacol 206: 169-175.
34. Mazumder DN, Das Gupta J, Santra A, Pal A, Ghose A, Sarkar S. 1998. Chronic arsenic toxicity in west Bengal-The worst calamity in the world. J Indian Med Assoc 96: 4-7, 18.
35. Mazumder DN, Steinmaus C, Bhattacharya P, von Ehrenstein OS, Ghosh N, Gotway M, Sil A, Balmes JR, Haque R, Hira-Smith MM, et al. 2005. Bronchiectasis in persons with skin lesions resulting from arsenic in drinking water. Epidemiology 16: 760-765.
36. Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E. 2008. Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA 300: 814-822.
37. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, et al. 1999. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94: 3315-3324.
38. Santra A, Maiti A, Chowdhury A, Mazumder DN. 2000a. Oxidative stress in liver of mice exposed to arsenic-contaminated water. Indian J Gastroenterol 19: 112-115.
39. Santra A, Maiti A, Das S, Lahiri S, Charkaborty SK, Mazumder DN. 2000b. Hepatic damage caused by chronic arsenic toxicity in experimental animals. J Toxicol Clin Toxicol 38: 395-405.
40. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360.
41. Shraim A, Cui X, Li S, Ng JC, Wang J, Jin Y, Liu Y, Guo L, Li D, Wang S, et al. 2003. Arsenic speciation in the urine and hair of individuals exposed to airborne arsenic through coal-burning in Guizhou, PR China. Toxicol Lett 137: 35-48.
42. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, et al. 2001. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19: 3852-3860.
43. Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH. 2005. Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14: 919-924.
44. Styblo M, Drobna Z, Jaspers I, Lin S, Thomas DJ. 2002. The role of biomethylation in toxicity and carcinogenicity of arsenic: A research update. Environ Health Perspect 110(Suppl 5): 767-771.
45. Sun G, Li X, Pi J, Sun Y, Li B, Jin Y, Xu Y. 2006. Current research problems of chronic arsenicosis in China. J Health Popul Nutr 24: 176-181.
46. Sun G, Xu Y, Li X, Jin Y, Li B, Sun X. 2007. Urinary arsenic metabolites in children and adults exposed to arsenic in drinking water in Inner Mongolia, China. Environ Health Perspect 115: 648-652.
47. Tallman MS. 2008. What is the role of arsenic in newly diagnosed APL? Best Pract Res Clin Haematol 21: 659-666.
48. Thomas DJ, Styblo M, Lin S. 2001. The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176: 127-144.
49. Tondel M, Rahman M, Magnuson A, Chowdhury IA, Faruquee MH, Ahmad SA. 1999. The relationship of arsenic levels in drinking water and the prevalence rate of skin lesions in Bangladesh. Environ Health Perspect 107: 727-729.
50. Tseng CH. 2007. Arsenic methylation, urinary arsenic metabolites and human diseases: Current perspective. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25: 1-22.
51. Tseng CH. 2009. A review on environmental factors regulating arsenic methylation in humans. Toxicol Appl Pharmacol 235: 338-350.
52. Tseng CH, Huang YK, Huang YL, Chung CJ, Yang MH, Chen CJ, Hsueh YM. 2005. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol 206: 299-308.
53. Tseng CH, Tai TY, Chong CK, Tseng CP, Lai MS, Lin BJ, Chiou HY, Hsueh YM, Hsu KH, Chen CJ. 2000. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: A cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect 108: 847-851.
54. Vahter M. 1994. Species differences in the metabolism of arsenic compounds. Appl Organomet Chem 8: 175-182.
55. Vahter M. 1999. Methylation of inorganic arsenic in different mammalian species and population groups. Sci Prog 82: 69-88.
56. Vahter M. 2000. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett 112: 209-217.
57. Vahter M. 2002. Mechanisms of arsenic biotransformation. Toxicology 181: 211-217.
58. Xu Y, Wang Y, Zheng Q, Li B, Li X, Jin Y, Lv X, Qu G, Sun G. 2008a. Clinical manifestations and arsenic methylation after a rare subacute arsenic poisoning accident. Toxicol Sci 103: 278-284.
59. Xu Y, Wang Y, Zheng Q, Li X, Li B, Jin Y, Sun X, Sun G. 2008b. Association of oxidative stress with arsenic methylation in chronic arsenic-exposed children and adults. Toxicol Appl Pharmacol 232: 142-149.
60. Xu YY, Wang Y, Li X, He M, Xue P, Fu JQ, Wang HH, Sun GF. 2009. Variations in arsenic methylation capacity and oxidative DNA lesions over a 2-year period in a high arsenic-exposed population. Int Arch Occup Environ Health 82: 251-258.
61. Yamauchi H, Yamamura Y. 1984. Metabolism and excretion of orally administered dimethylarsinic acid in the hamster. Toxicol Appl Pharmacol 74: 134-140.
62. 3) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents 13: 195-200.